Literature DB >> 8608780

Radioiodine therapy for thyroid cancer.

D C Sweeney1, G S Johnston.   

Abstract

A small abut important subset of patients with differentiated thyroid cancer will die of disease. Our approach to therapy treats almost all patients similarly, with aggressive surgery and I-131 therapy. Meticulous follow-up should include multiple I-131 diagnostic scans using at least 5 to 10 mCi of I-131 with attention to proper patient preparation and good quality procedures. Thyroglobulin levels should be monitored, and other radiographic diagnostic procedures, including thallium scans and MR imaging, should be used as needed. Until screening tests are discovered which will accurately pinpoint patients at high risk for aggressive, recurrent thyroid cancer, the best course of action appears to be aggressive management, including radioiodine therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8608780

Source DB:  PubMed          Journal:  Endocrinol Metab Clin North Am        ISSN: 0889-8529            Impact factor:   4.741


  8 in total

1.  Preservation of recurrent laryngeal nerve invaded by differentiated thyroid cancer.

Authors:  T Nishida; K Nakao; M Hamaji; W Kamiike; K Kurozumi; H Matsuda
Journal:  Ann Surg       Date:  1997-07       Impact factor: 12.969

2.  Risk-stratified management of well-differentiated thyroid cancers: a review of experience from a single institution, 1990-2003.

Authors:  M H Chew; G Chan; M M A Siddiqui; B C Tai; R Sivanandan; K C Soo; D T H Lim
Journal:  World J Surg       Date:  2008-03       Impact factor: 3.352

3.  Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer.

Authors:  Sepideh Gholami; Chun-Hao Chen; Emil Lou; Laurence J Belin; Sho Fujisawa; Valerie A Longo; Nanhai G Chen; Mithat Gönen; Pat B Zanzonico; Aladar A Szalay; Yuman Fong
Journal:  FASEB J       Date:  2013-11-01       Impact factor: 5.191

Review 4.  Special variants of differentiated thyroid cancer: does it alter the extent of surgery versus well-differentiated thyroid cancer?

Authors:  Tobias Carling; Idris T Ocal; Robert Udelsman
Journal:  World J Surg       Date:  2007-05       Impact factor: 3.352

5.  Recombinant TSH stimulated remnant ablation therapy in thyroid cancer: the success rate depends on the definition of ablation success--an observational study.

Authors:  Anouk N A van der Horst-Schrivers; Wim J Sluiter; Anneke C Muller Kobold; Bruce H R Wolffenbuttel; John T M Plukker; Peter H Bisschop; John M de Klerk; Imad Al Younis; Paul Lips; Jan W Smit; Adrienne H Brouwers; Thera P Links
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

6.  The effect of high dose radioiodine therapy on formation of radiation retinopathy during thyroid cancer treatment.

Authors:  Tülay Kaçar Güveli; Sezer Özkan; Müge Öner Tamam; Ercan Uyanık; Nurcan Ediz; Mehmet Mülazımoğlu; Tevfik Özpaçacı
Journal:  Mol Imaging Radionucl Ther       Date:  2014-10-05

7.  Both F-18 FDG-avidity and Malignant Shape of Cervical Lymph Nodes on PET/CT after Total Thyroidectomy Predict Resistance to High-dose I-131 Therapy in Patients with Papillary Thyroid Cancer.

Authors:  Byung Hyun Byun; Seong Young Kwon; Ari Chong; Jahae Kim; Su Woong Yoo; Jung-Joon Min; Ho-Chun Song; Henry Hee-Seung Bom
Journal:  Asia Ocean J Nucl Med Biol       Date:  2013

8.  Long-term results after treatment of very low-, low-, and high-risk thyroid cancers in a combined setting of thyroidectomy and radio ablation therapy in euthyroidism.

Authors:  Nikos Emmanouilidis; Harald Schrem; Michael Winkler; Jürgen Klempnauer; Georg F W Scheumann
Journal:  Int J Endocrinol       Date:  2013-07-09       Impact factor: 3.257

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.